Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease: A Phase 2 Trial

BACKGROUND: Imatinib is the current standard frontline therapy for chronic myelogenous leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic response (CCyR); however, complete molecular responses are infrequent. The Bcr-Abl fusion creates a unique sequence of amino aci...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer
Auteurs principaux: Jain, Nitin, Reuben, James M., Kantarjian, Hagop, Li, Changping, Gao, Hui, Lee, Bang-Ning, Cohen, Evan N., Ebarb, Theresa, Scheinberg, David A., Cortes, Jorge
Format: Artigo
Langue:Inglês
Publié: 2009
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5534348/
https://ncbi.nlm.nih.gov/pubmed/19536894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24468
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires